Deciphera, a subsidiary of Japan’s Ono Pharmaceutical, has received approval from the European Commission (EC) for Romvimza (vimseltinib) for the treatment of adult patients with symptomatic ...

Regeneron Pharmaceuticals has announced the primary endpoint was met in the Phase III OPTIMA trial investigating garetosmab ...

China’s Mabwell (688062.SH) and Californian biotech venture firm Aditum Bio have combined to launch Kalexo Bio.

The biologics supply chain has shifted from a technical backwater into a political and regulatory battleground. Vectors, ...

The European Commission (EC) has granted marketing authorization for US biotech major Biogen’s Zurzuvae (zuranolone) to treat ...